MAP1LC3A and Alzheimer disease: (32) found that AD-MSC-EVs inhibited p62/LC3 and mTOR signaling pathways, increased the levels of autophagy-related proteins, and ameliorated cell damage of podocyte by inhibiting the signaling pathway of miR-486/Smad1/mTOR.